Presentation is loading. Please wait.

Presentation is loading. Please wait.

Case for androgens Giorgio Arnaldi Clinica di Endocrinologia

Similar presentations


Presentation on theme: "Case for androgens Giorgio Arnaldi Clinica di Endocrinologia"— Presentation transcript:

1 Case for androgens Giorgio Arnaldi Clinica di Endocrinologia
AOU Ospedali Riuniti Ancona Ancona

2 Adrenal androgens and bone
Agenda Physiology of adrenal androgens , i.e. DHEA Effects of adrenal androgens on bone DHEA treatment in post-menopausal women DHEA treatment and bone effects in Addison

3 DHEA and DHEAS are the most abundant steroids in humans
Adult 6-month old infant 10 000 10 20 30 40 50 60 70 Fetal Period DHEAS nmol l-1 Age (years) Man Woman Birth At yr, DHEA has already decreased by 70% The individual variability across adulthood is substantial and the normal range of serum DHEA(S) is therefore very wide at each decade of life

4 DHEA exerts its primary effects through its estrogenic and androgenic metabolites
Labrie 2007

5 A specific DHEA receptor has not been characterized
Although DHEA may be converted to DHEAS by SULT2A1, no relevant amounts of DHEA result from conversion of DHEAS. Therefore, DHEAS levels, which are measured in the routine clinical practice, may not always reflect the amount of available DHEA. In women, exogenous DHEA is mainly converted to androgens. An increase in serum androgens is observed only in men with low androgen levels Lang et al BP&R Clin Endocrinol Metab 2015

6 Adrenal androgens and bone
Agenda Physiology of adrenal androgens , i.e. DHEA Effects of adrenal androgens on bone DHEA treatment in post-menopausal women DHEA treatment and bone effects in Addison

7

8 A specific bone DHEA receptor ?

9 “These findings suggest that the hyperandrogenism observed in Premature Adrenarche may directly or indirectly affect bone mineral mass….”

10 DHEAS correlates negatively with bone turnover before peak mass
DHEA and its metabolites are independent determinants of cortical density, particularly before the activation of pubertal sex hormones Remer, T et al. Adrenarche and bone modeling and remodeling at the proximal radius: weak androgens make stronger cortical bone in healthy children. Journal of Bone and Mineral Research, 18, 1539– DHEAS correlates negatively with bone turnover before peak mass Walsh, J.S. et al Hormonal determinants of bone turnover before and after attainment of peak bone mass. Clinical Endocrinology (Oxf), 72, 320– DHEAS, androstenedione and estrone were positive predictors of bone age (….but they were not associated with bone density) Vandewalle S et al. Relation of adrenal-derived steroids with bone maturation, mineral density andgeometry in healthy prepubertal and early pubertal boys. Bone. 69:

11 Eighty CAH adults (47 classic, 33 nonclassic)
low DHEAS may be associated with weak cortical bone independent of glucocorticoid exposure. DHEAS was the only independent significant predictor of BMD at the forearm and spine In a multivariate analysis after adjusting for age, gender, height standard deviation, phenotype and cumulative glucocorticoid exposure, higher DHEAS was independently associated with higher BMD at the spine, radius and whole body.

12

13 Adrenal androgens and bone
Agenda Physiology of adrenal androgens , i.e. DHEA Effects of adrenal androgens on bone DHEA treatment in post-menopausal women DHEA treatment and bone effects in Addison

14 Exogenous DHEA treatment
When administered to postmenopausal women, DHEA is mainly transformed to androgens rather than estrogens. Using liquid chromatography combined with tandem mass spectrometry, an oral dose of DHEA 50 mg daily for 12 months increases: estrone 34% and estradiol 57% total testosterone about 100%, DHT relatively unchanged Davis et al J Clin Endocrinol Metab, 2011, 96(6):1642–1653

15 Labrie et al J Clin Endocrinol Metab, 82:3498–3512, 1997
DHEA was administered percutaneously once daily in the morning as a 10% cream 14 women (60 to 70 yr) Total hip +2% at 12 months Labrie et al J Clin Endocrinol Metab, 82:3498–3512, 1997

16 The effect is small in relation to other treatment
Effects of DHEA on bone in postmenopausal women in placebo-controlled trials The effect is small in relation to other treatment No fractures data are available Over 26 weeks 640 women Davis et al J Clin Endocrinol Metab, 2011, 96(6):1642–1653

17 Adrenal androgens and bone
Agenda Physiology of adrenal androgens , i.e. DHEA Effects of adrenal androgens on bone DHEA treatment in post-menopausal women DHEA treatment and bone effects in Addison

18 Adrenal insufficiency
Replacement therapy Glucocorticoid Mineralocorticoid (Addison only) DHEAS (?) In both primary and secondary adrenal insufficiency, DHEA secretion is clearly decreased and often even absent. In women, it results in significant androgen deficiency whereas testicular testosterone is preserved in men.

19 Gurnell et al Double-blind trial, randomized 106 subjects (44 males, 62 females) with Addison’s disease to receive either 50 mg daily of micronized DHEA or placebo orally for 12 months DHEA reversed ongoing loss of bone mineral density at the femoral neck (P 0.05) but not at other sites. The improvement was modest comparing other treatment

20 10 female patients (median age 38
10 female patients (median age 38.5 years, range 28–52) with adrenal failure were treated with DHEA 50 mg for 6 months in a double-blind, randomized, placebo-controlled, and crossover study

21 on muscle, fat, and bone tissue Frequent adverse effects
No effects and on fuel metabolism Frequent adverse effects 10 female patients (median age 38.5 years, range 28–52) with adrenal failure were treated with DHEA 50 mg for 6 months in a double-blind, randomized, placebo-controlled, and crossover study

22

23 J Intern Med. 2014;275:

24


Download ppt "Case for androgens Giorgio Arnaldi Clinica di Endocrinologia"

Similar presentations


Ads by Google